Clinical Trial Update: Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating retreatment with Lutathera (lutetium Lu-177 dotatate) in patients with new progression of intestinal well-differentiated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intestinal Neuroendocrine Tumor
• Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle | Conditions: Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor | Phase 2 | Status: RECRUITING